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TumorigenesisMesenchymal stem cells stimulate tumor growth in vivo through a lysophosphatidic acid (LPA)-dependent
mechanism. However, the molecular mechanism by which mesenchymal stem cells stimulate tumorigenesis is
largely elusive. In the present study, we demonstrate that conditioned medium from A549 human lung
adenocarcinoma cells (A549 CM) induces expression of periostin, an extracellularmatrix protein, in human adipose
tissue-derived mesenchymal stem cells (hASCs). A549 CM-stimulated periostin expression was abrogated by
pretreatment of hASCswith the LPA receptor 1 (LPA1) inhibitor Ki16425 or short hairpin RNA-mediated silencing of
LPA1, suggesting a key role of the LPA–LPA1 signaling axis in A549 CM-stimulated periostin expression. Using a
xenograft transplantation model of A549 cells, we demonstrated that co-injection of hASCs potentiated tumor
growth of A549 cells in vivo and that co-transplanted hASCs expressed not only periostin but alsoα-smoothmuscle
actin (α-SMA), amarker of carcinoma-associated ﬁbroblasts. Small interfering RNA- or short hairpin RNA-mediated
silencing of periostin resulted in blockade of LPA-induced α-SMA expression in hASCs. In addition, silencing of
periostin resulted in blockade of hASC-stimulated growth of A549 xenograft tumors and in vivo differentiation of
transplanted hASCs to α-SMA-positive carcinoma-associated ﬁbroblasts. Conditioned medium derived from LPA-
treated hASCs (LPA CM) potentiated proliferation and adhesion of A549 cells and short interfering RNA-mediated
silencing or immunodepletion of periostin from LPA CM abrogated proliferation and adhesion of A549 cells. These
results suggest a pivotal role for hASC-secreted periostin in growth of A549 xenograft tumors within the tumor
microenvironment.49 CM, conditioned medium
; CM-Dil, chloromethylbenza-
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3-phosphate dehydrogenase;
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Tumors are composed of neoplastic cells and non-neoplastic stromal
cell components, including ﬁbroblasts,myoﬁbroblasts, endothelial cells,pericytes, and inﬂammatory cells [1]. Carcinoma-associated ﬁbroblasts
(CAFs, also known as myoﬁbroblasts or cancer stroma), which express
α-smooth muscle actin (α-SMA) as a phenotypic marker, have been
shown to play important roles during cancerprogression andmetastasis
[2,3]. They stimulate tumorigenesis, angiogenesis, and invasion in a
variety of solid tumors, including prostate, breast, and ovarian
carcinomas [1,4–7] by secretion of various extracellularmatrix proteins,
proteases, chemokines, and angiogenic factors [8]. Co-transplantation of
CAFs has been shown to stimulate invasiveness of prostate and breast
tumors in a xenograft tumor model [6,7]. CAFs have been reported to
originate from various cell types, including tissue-resident ﬁbroblasts,
cancer cells or epithelial cells undergoing epithelial-to-mesenchymal
transition, or mesenchymal stem cells [2].
Mesenchymal stem cells (MSCs) have a capacity for self-renewal,
long-term viability, and differentiation potential toward diverse cell
types, including adipogenic, osteogenic, chondrogenic, and myogenic
lineages [9–12], suggesting clinical usefulness of MSCs for tissue
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peripheral tissues where they are thought to serve as local sources of
tissue-resident stem cells [13]. In addition, recruitment of bone
marrow-derived MSCs into the stroma of developing tumors has been
reported [14]. MSCs constitute a large proportion of non-neoplastic
stromal cells within the tumor microenvironment [2]. Accumulating
evidence suggests that MSCs have an adverse effect that favors tumor
growth: when transplanted subcutaneously, tumor cells mixed with
MSCs exhibited elevated capability of proliferation and rich angio-
genesis in tumor tissues [15]. In addition, MSCs co-injected with
human breast carcinoma cells into a subcutaneous site by xenograft
transplantation stimulated metastatic potency of breast carcinoma
[16]. Furthermore, human bone marrow-derived MSCs exposed to
tumor-conditionedmediumhave been reported to exhibit phenotypic
characteristics and ability of CAFs in promotion of tumor cell growth
in vitro and in an in vivo co-implantation model [17]. These results
suggest regulation of tumor growth and metastasis in vivo through
paracrine crosstalk between MSCs and cancer cells.
Lysophosphatidic acid (LPA) is a small bioactive phospholipid
produced by activated platelets, mesothelial cells, ﬁbroblasts, adipo-
cytes, and some cancer cells [18–20]. Accumulating evidence suggests
that LPA is implicated in tumorigenesis and metastasis [19]. We have
previously reported that LPA induced migration of human adipose
tissue-derived MSCs (hASCs) and stimulated differentiation of cells to
α-SMA-positive CAFs [21,22], suggesting a pivotal role of LPA in
generation of CAFs within the tumor microenvironment. Co-trans-
plantation of hASCs with A549 human lung adenocarcinoma
stimulated growth of xenograft tumors in vivo and short hairpin
RNA (shRNA)-mediated silencing of LPA receptor 1 (LPA1) in hASCs
abrogated hASC-stimulated in vivo growth of A549 xenograft tumors
[23]. In addition, conditioned medium from A549 cells (A549 CM)
contained signiﬁcant levels of LPA and elicited differentiation of hASCs
to α-SMA-positive CAFs through an LPA1-dependent mechanism in
vitro [23]. These results suggest that hASCs can be differentiated to α-
SMA-positive CAFs through an LPA–LPA1-dependent mechanism
within the tumor microenvironment. However, the molecular
mechanisms by which hASCs stimulate in vivo growth of A549
xenograft tumors are still elusive.
Periostin, originally named osteoblast-speciﬁc factor-2, is a
disulﬁde-linked 90-kDa secretory protein that functions as a cell
adhesion molecule. It shares a structural homology to insect fasciclin I
and supports adhesion of osteoblasts, thereby functioning in
recruitment and attachment of osteoblasts to the periosteum [24].
In addition to its role in bone physiology, accumulating evidence has
demonstrated involvement of periostin in tumor growth and survival,
angiogenesis, and metastasis [25]: high expression of periostin has
been associated with tumor size, lymph node metastasis, disease
stage, and lymphatic invasion in non-small cell lung cancer patients
[26]. Furthermore, over-expression of periostin in patients with lung
cancer has been correlated with clinicopathological data, including
squamous cell carcinoma type, higher stage, vessel inﬁltration, and
tumor relapse [27]. Ectopic over-expression of periostin promoted
proliferation and migration of A549 cells in vitro [28]. We previously
reported on high expression of periostin in CAFs of epithelial ovarian
cancer tissues [29]. In addition, conditioned medium from ovarian
cancer cells stimulated expression of not only α-SMA but also
periostin in hASCs through an LPA1-dependent mechanism [29],
implying a possible role of periostin as an hASC-derived paracrine
factor. However, involvement of hASC-secreted periostin in tumori-
genesis has not been explored.
In order to clarify the paracrine mechanisms involved in the crosstalk
between cancer cells and hASCs, we explored the role of hASC-secreted
periostin in tumor growth using an in vivo xenograft co-transplantation
model of A549 cells. Thepresent studydemonstrates for theﬁrst time that
periostin plays a pivotal role in adhesion and proliferation of A549 cells as
a paracrine factor secreted from hASCs.2. Materials and methods
2.1. Materials
Trypsin, α-minimum essential medium, fetal bovine serum, Alexa
Fluor488goat anti-rabbit, andAlexaFluor647goat anti-mouseantibodies
were purchased from Invitrogen (Carlsbad, CA, http://www.invitrogen.
com). Anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) anti-
body was purchased fromMillipore (Temecula, CA, http://www.milliore.
com). 1-Oleoyl-sn-glycero-3-phosphate (LPA), Ki16425, and anti-α-SMA
antibodywerepurchased fromSigma-Aldrich (St. Louis,MO, http://www.
sigmaaldrich.com). Anti-periostin antibody was purchased from Abcam
(Cambridge, MA). Recombinant human periostin was purchased from
R&D Systems, Inc. (Minneapolis, MN, http://www.rndsystems.com).
Vectashield mounting medium with 4′-6-Diamidino-2-phenylindole
(DAPI) was purchased from Vector Laboratories (Burlingame, CA, http://
vectorlabs.com). Culture plates were purchased from Nunc (Roskilde,
Denmark, http://www.nuncbrand.com). Peroxidase-labeled secondary
antibodies and system were purchased from Amersham Biosciences
(Pittsburgh, PA, http://www4.gelifesciences.com).
2.2. Cell culture
hASCs were isolated from subcutaneous adipose tissues, which
were obtained from elective surgeries with patient's consent as
approved by the Institutional Review Board of Pusan National
University Hospital. For isolation of hASCs, adipose tissues were
washed at least three times with sterile PBS and treated with an equal
volume of collagenase type I suspension (1 g/l of HBSS buffer with 1%
bovine serum albumin) for 60 min at 37 °C with intermittent shaking.
Floating adipocyteswere separated from the stromal–vascular fraction
by centrifugation at 300×g for 5 min. The cell pellet was re-suspended
inα-minimum essential medium supplementedwith 10% fetal bovine
serum, 100 U/ml penicillin, and100 μg/ml streptomycin and cellswere
plated in tissue culture dishes at 3500 cells/cm2. Primary hASCs were
cultured for 4–5 days until they reached conﬂuence and were deﬁned
as passage “0”. The passage number of hASCs used in these
experiments was 3–10. Human lung adenocarcinoma A549 cells
were obtained from the American Tissue Type Culture (Rockville, MD,
http://www.atcc.org) andmaintained in RPMImedium supplemented
with 10% FBS at 37 °C.
2.3. Preparation of conditioned medium
For preparation of conditionedmedium from A549 cells, cells were
seeded on 100-mmcell culture dishes and cultured in growthmedium
until reaching conﬂuence. Cells were brieﬂy rinsed twice with PBS,
followed by incubation with 10 ml of serum-free α-minimum
essential medium for 48 h prior to collection of culture medium. For
collection of conditionedmedium from hASCs, cells were treated with
fresh serum-freeα-minimumessentialmediumcontaining vehicles or
LPA for 48 h. Culture supernatants were centrifuged at 2000 rpm for
10 min for removal of cell debris, followed by ﬁltering with 0.45 μm
Millipore syringe ﬁlters (Millipore, Bedford, MA), and storage at
−70 °C for subsequent use.
2.4. Cell adhesion and proliferation assays
To explore the effect of periostin on adhesion ability of A549 cells,
ninety six-well microculture plates (Falcon, Becton-Dickinson, Mountain
View, CA) were incubated with recombinant periostin proteins at 37 °C
for 12 h, followed by blocking with PBS containing 0.2% BSA for 1 h at
37 °C. A549 cells were trypsinized and suspended in the culture media at
a density of 2×105 cells/ml, and 0.1 ml of the cell suspension was then
added to each well of the plates. Following incubation for 1 h at 37 °C,
unattached cells were removed by rinsing twice with PBS. Cells were
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hematoxylin and eosin for determination of the number of attached cells.
To explore the effects of recombinant periostin or conditioned
medium from hASCs on cell proliferation of A549 cells, a colorimetric
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay was used: MTT is metabolized by NAD-dependent
dehydrogenase to form a colored reaction product (formazan), and
the amount of dye formed correlates directly with the number of cells.
For determination of cell numbers, hASCs were seeded in a 24-well
culture plate at a density of 2×104 cells/well, cultured for 48 h in
normal growth medium, serum-starved for 24 h, and treated with
various reagents (or a vehicle control) for the indicated times. Cells
were washed twice with PBS and incubated with 100 μl of MTT
(0.5 mg/ml) for 2 h at 37 °C. Formazan granules generated by the cells
were dissolved in 100 μl of dimethylsulfoxide, and the absorbance of
the solution at 562 nm was determined using a PowerWavex
microplate spectrophotometer (Bio-Tek Instruments, Inc.; Winooski,
VT) after dilution to a linear range.
2.5. Western blotting
Expression levels of α-SMA and periostin were determined by
Western blotting analysis. Serum-starved hASCs were treated with
appropriate conditions, washed with ice-cold PBS, and then lysed in
lysis buffer (20mM Tris–HCl, 1 mM EGTA, 1 mM EDTA, 10 mM NaCl,
0.1 mM phenylmethylsulfonyl ﬂuoride, 1 mM Na3VO4, 30 mM sodium
pyrophosphate, 25 mM β-glycerol phosphate, 1% Triton X-100, pH 7.4).
Lysates were resolved by SDS-PAGE, transferred onto a nitrocellulose
membrane, and then stained with 0.1% Ponceau S solution (Sigma-
Aldrich). After blocking with 5% nonfat milk, the membranes were
immunoblotted with various antibodies, and bound antibodies were
visualized with horseradish peroxidase-conjugated secondary antibodies
using the enhanced chemiluminescence Western blotting system (ECL,
Amersham Biosciences).
2.6. Gene silencing using shRNA lentivirus or small interfering RNA (siRNA)
cpLKO.1-puro lentiviral vectors expressing LPA1 shRNA
(TRCN0000011368), periostin shRNA(TRCN0000123054), andnon-target
control shRNA (SHC002) were purchased from Sigma-Aldrich. Functional
sequences in the shRNA vectors are as follows: LPA1, “CCGGCCTTCTGAA-
GACTGTGGTCATCTCGAGATGACCACAGTCTTCAGAAGGTTTTT” to target
the LPA1 gene sequence (CCTTCTGAAGACTGTGGTCAT); sh-periostin,
“CCGGCGAGCCTTGTATGTATGTTATCTCGAGATAACATACATA-
CAAGGCTCGTTTTTG” to target the periostin gene sequence (CGAGCCTTG-
TATGTATGTTAT). For generation of lentiviral particles, HEK293FT cells
were co-transfectedwith the shRNA lentiviral plasmid (pLKO.1-puro) and
ViraPower Lentiviral packaging mix (pLP1, pLP2, pLP-VSV-G; Invitrogen)
using Lipofectamine 2000 (Invitrogen) and culture supernatants contain-
ing lentivirus were harvested at 48 h after transfection. For lentiviral
transduction, hASCs were treated with culture supernatants from
HEK293FT cells in the presence of 5 μg/ml polybrene (Sigma-Aldrich)
and stable cell lines expressing shRNA were generated by selection with
puromycin (5 μg/ml). To ensure shRNA-mediated silencing of LPA1 and
periostin expression, mRNA levels of LPA1, periostin, and GAPDH were
determined by RT-PCR analysis.
For siRNA experiments, hASCs were seeded on 60 mm-diameter
dishes. At 70% conﬂuence, cells were transfectedwith appropriate siRNAs
using Lipofectamine 2000 reagent according to the manufacturer's
instructions (Invitrogen). Periostin siRNA duplexes were synthesized,
desalted, and puriﬁed by Samchully Pharm. Co. Ltd. (Siheung, GyeongGi,
Korea) as follows: periostin 5′-CCGAAGCUCUUAUGAAGUATT-3′ (sense)
and 5′-UACUUCAUAAGAGCUUCGGTT-3′ (anti-sense). Nonspeciﬁc con-
trol siRNAwaspurchased fromDharmacon (Lafayette, CO). Lipofectamine
2000 reagent was incubated with serum-free medium for 10 min,
followedbyadditionof respective siRNAs to themixtures.After incubationfor 15 min at room temperature, the mixtures were diluted with serum-
free medium and added to each well to a ﬁnal concentration of 100 nM.
Following incubation of hASCswith siRNAs for 6 h, the cellswere cultured
in growthmedium for 24 h, and expression levels of periostin andGAPDH
were determined by Western blotting.
2.7. In vivo xenograft tumorigenesis model
BALB/c–nu/nu mice were randomly divided into three groups (nine
mice in each group). hASCs were labeledwith the ﬂuorescent cell surface
marker chloromethylbenzamide-1,1′-diactaolecyl-3,3,3′,3′-tetramethy-
lindocarbocyanine perchlorate (CM-Dil) (Invitrogen, Carlsbad, CA,
http://probes.invitrogen.com) prior to transplantation. Mice received
subcutaneous administration of A549 cells (1×106 cells/60 μl PBS) alone
or mixed with hASCs (1×106 hASCs plus 1×106 A549 cells/60 μl PBS)
into the front of the backside. Micewere examined 2 times perweek, and
tumor volumewas evaluated bymeasurement of the length andwidth of
the tumor mass in millimeters (mm) using electronic vernier calipers.
Tumor volume (mm3) was calculated using the formula V=
(length×width×width)/2. After 4 weeks, mice were sacriﬁced, and
weights of xenograft tumors were quantiﬁed.
2.8. Immunostaining and analysis of images
Immunohistochemistry was performed using the streptavidin–
peroxidase techniqueand theDAKOEnVisionSystem(DakoCytomation,
Hamburg, Germany). Consecutive parafﬁn-embedded tissue sections
(2.5-μm thick) were deparafﬁnized and rehydrated. For antigen
retrieval, slideswere pretreated in citrate buffer (pH6.0) in amicrowave
oven for 12 min. Slides were then cooled to room temperature in
deionized water for 5 min. Endogenous peroxidase activity was
quenched by incubation of the slides in methanol containing 0.3%
hydrogen peroxide, followed by washing with deionized water for
3 min, after which the sections were incubated for 1 h at room
temperature with normal goat serum, and subsequently incubated at
room temperature for 1 h with the primary anti-α-SMA (Sigma; 1:200
dilution) antibody. Next, the sections were rinsed with washing buffer
(PBS containing 0.5% Tween 20) and incubated with biotinylated anti-
mouse IgG and streptavidin–peroxidase complex, followed by reaction
with diaminobenzidine and counterstaining with Mayer's hematoxylin.
In addition, to conﬁrm the speciﬁcity of the primary antibody and the
technique used, tissue sections were incubated in the absence of the
primary antibody andwith negative control IgG. Under these conditions,
no speciﬁc immunostaining was detected.
Immunostaining and confocal microscopy were used for determina-
tion of the cellular expression patterns of proteins within xenograft
tumor tissues. For immunostaining, specimens were incubated with
anti-α-SMA or anti-periostin antibodies for 2 h, followed by incubation
with Alexa Fluor 488-conjugated anti-rabbit or Alexa Fluor 647-
conjugated anti-mouse secondary antibodies (Molecular Probes) for
1 h. The specimens were ﬁnally washed and mounted in Vectashield
medium with DAPI for visualization of nuclei. A Leica TCL-SP2 confocal
microscope system was used for collection of images of CM-Dil-,
periostin-, or α-SMA-positive cells and DAPI-positive nuclei. Images of
four random non-overlapping microscopic ﬁelds of view per xenograft
tumorwere captured at high powermagniﬁcation (400×). Using the co-
localization Finder plugin of Image J software (NIH, http://rsb.info.nih.
gov/ij/plugins/colocalization.html), we measured α-SMA-positive and
CM-Dil-positive areas in the images. Relative percentages of α-SMA-
positive cells versus CM-Dil-positive cellswere calculated as percentages
of the CM-Dil-positive area.
2.9. Statistical analysis
Results of multiple observations are presented as mean±SD.
Student's t test was used for analysis of differences between the two
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used for assessment of group differences, followed by post hoc com-
parison test using Scheffe's method.
3. Results
3.1. A549 CM stimulates expression of periostin in hASCs through an
LPA–LPA1-dependent mechanism
LPA–LPA1-dependent paracrine signaling played a key role in
differentiation of hASCs to α-SMA-positive CAFs in an in vivo
xenograft co-transplantation model of A549 cancer cells and hASCs
[21,23]. In order to determine whether paracrine signaling from A549
cells can regulate periostin expression in hASCs, we examined
expression levels of periostin after exposure of cells to A549 CM for
4 days. As shown in Fig. 1A, A549 CM induced a dose-dependent
increase of the expression levels of not only α-SMA but also periostin
in hASCs, suggesting that A549-derived paracrine factors stimulate
periostin expression in hASCs. To determine whether LPA is
responsible for A549 CM-stimulated periostin expression, we exam-
ined the effect of LPA on the expression levels of periostin in hASCs. As
shown in Fig. 1B, expression levels of both periostin and α-SMA
showed a dose-dependent increase by exposure of the cells to LPA,
with maximal stimulation at 10 μM concentration. LPA treatment
resulted in time-dependent augmentation of the expression levels of
periostin and α-SMA, with maximal stimulation on day 4. Of
particular interest, LPA-induced periostin expression was detectedFig. 1. A549 CM stimulates expression of periostin and α-SMA in hASCs through an LPA
concentrations of A549 CM for 4 days. (B) Serum-starved hASCs were treated with indicate
(0.1% fatty acid-free BSA) or 10 μM LPA for the indicated time periods. (D) Serum-starved hA
10 μM Ki16425. (E) hASCs were infected with sh-control or sh-LPA1 lentivirus, followed by t
SMA, and GAPDH were determined by Western blotting. Representative data from three inat 6 h after exposure of hASCs to LPA, while increased α-SMA
expression was observed after LPA treatment for 2 days (Fig. 1C),
suggesting that periostin expression occurred in advance of α-SMA
expression. In order to determine whether LPA is involved in A549
CM-induced periostin expression, we examined the effects of
Ki16425, an antagonist speciﬁc to LPA1/3 receptors, on periostin
expression induced by LPA and A549 CM. As shown in Fig. 1D,
treatment of cells with 1 μM Ki16425 resulted in complete abrogation
of the expression levels of both α-SMA and periostin, which were
stimulated by LPA and A549 CM. To further support these results, we
depleted endogenous LPA1/EDG2, a major isoform of LPA receptors
expressed in hASCs [30], using shRNA lentivirus. As shown in Fig. 1E,
LPA1 shRNA attenuated expression ofα-SMA and periostin induced by
either LPA or A549 CM. These results suggest a key role of the LPA–
LPA1 signaling pathway in A549 CM-induced expression of not only
α-SMA but also periostin in hASCs.3.2. Periostin is involved in LPA-induced α-SMA expression in hASCs
For determination of whether periostin is involved in LPA-
stimulated α-SMA expression, we examined the effects of siRNA- or
shRNA-mediated depletion of endogenous periostin on LPA-induced
α-SMA expression. LPA-stimulated periostin expression was abro-
gated by siRNA transfection or shRNA lentiviral transduction (Fig. 2A
and B). Of particular interest, LPA-stimulated α-SMA expression was
also blocked by siRNA- or shRNA-mediated silencing of periostin–LPA1-dependent mechanism. (A) Serum-starved hASCs were exposed to increasing
d concentrations of LPA for 4 days. (C) Serum-starved hASCs were treated with vehicle
SCs were exposed to 50% A549 CM or 10 μM LPA for 4 days in the presence or absence of
reatment with 50% A549 CM or 10 μM LPA for 4 days. Expression levels of periostin, α-
dependent experiments are shown.
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for LPA-induced α-SMA expression.
3.3. Periostin is involved in hASC-stimulated in vivo growth of A549
human lung adenocarcinoma cells
hASCs co-transplanted with A549 cells in a xenograft tumor model
stimulated proliferation of tumor cells and tumor angiogenesis [23]. In
order to explore the role of periostin in hASC-stimulated tumor
growth, we depleted periostin expression using shRNA lentivirus, and
then performed subcutaneous co-transplantation of the cells with
A549 cells in nudemice. As shown in Fig. 3A, xenograft transplantation
of A549 cells resulted in formation of tumors, and co-transplantation
of A549 cells with control shRNA-infected hASCs (sh-control/hASCs)
resulted in a time-dependent increase of growth of xenograft tumors,
whereas co-transplantation of periostin shRNA-infected hASCs (sh-
periostin/hASCs) with A549 cells did not result in increased tumor
volume. Consistently, sh-control/hASCs, but not sh-periostin/hASCs,
induced an increase in theweights of A549 xenograft tumors (Fig. 3B–C),
suggesting a pivotal role of periostin in hASC-stimulated in vivo growth
of A549 cells.
3.4. Expression of periostin in hASCs-derived CAFs in xenograft tumor
tissues
We have reported on differentiation of co-transplanted hASCs
to α-SMA-positive CAFs in A549 xenograft tumors [23]. For
determination of whether periostin is involved in differentiation of
hASCs to CAFs in vivo, we examined expression of α-SMA in xenograft
tumors. As shown in Fig. 4A, α-SMA-positive CAFs were detected in
tumor tissues generated by xenograft transplantation of A549 cells.
An increase in the number of α-SMA-positive cells was observed in
xenograft tumors in which sh-control/hASCs were co-transplanted
with A549 cells. However, co-transplantation of sh-periostin/hASCs
together with A549 cells did not result in an increase in the number of
α-SMA-positive cells in xenograft tumors. These results suggest that
periostin expression is required for in vivo differentiation of hASCs to
α-SMA-positive CAFs in xenograft tumor tissues.
For determination of whether periostin is expressed in α-SMA-
positive CAFs, we performed immunoﬂuorescence double staining in
tumor tissues formed by co-transplantation of A549 cells with hASCs
labeled with the ﬂuorescent dye DM-Dil. Co-injection of sh-con-
trol/hASCs with A549 cells resulted in detection of α-SMA-positive
immunoreactivity primarily in CM-Dil-positive cells adjacent to
tumor cells in A549 xenograft tumor tissues, suggesting that hASCs
can differentiate to α-SMA-positive CAFs (Fig. 4B). Furthermore,
periostin immunoreactivity was mainly detected in both α-SMA-Fig. 2. Role of periostin in LPA-induced α-SMA expression in hASCs. (A) hASCs were
transfected with si-control or si-periostin, followed by treatment with 10 μM LPA or
vehicles for 4 days. (B) hASCswere infectedwith sh-control or sh-periostin lentiviruses,
followed by treatment with 10 μM LPA or vehicles for 4 days. Expression levels of α-
SMA, periostin, and GAPDH were determined by Western blotting. Representative data
from three independent experiments are shown.positive and CM-Dil-positive cells. However, CM-Dil-positive hASCs
expressed low levels of periostin and α-SMA in tumor tissues
generated by injection of sh-periostin/hASCs and A549 cells. To
ascertain the results, percentages of α-SMA- and periostin-positive
cells in CM-Dil-positive cells were counted. As shown in Fig. 4C,
approximately 65% cells of CM-Dil-positive sh-control/hASCs showed
high expression of both α-SMA and periostin. In contrast, 33% cells of
sh-periostin/hASCs expressed low levels of bothα-SMA and periostin.
These results suggest that periostin is expressed in α-SMA-positive
CAFs derived from hASCs in an A549 xenograft tumor model. To
explore the effect of hASC-derived periostin on in vivo growth of A549
cells, the relative ratio of the number of A549 cells to the number of
hASCs in the xenograft tumor tissues was determined by measuring
areas of CM-Dil-negative A549 cells and CM-Dil-positive hASCs. The
relative ratio of A549 cells to hASCs in xenograft tumor tissues
generated by co-injection of sh-periostin/hASCs and A549 cells was
markedly decreased comparedwith that of A549 cells in tumor tissues
transplanted with sh-control/hASCs plus A549 cells (Fig. 4D), while
the area of CM-Dil-positive hASCs was not signiﬁcantly affected by
silencing of periostin expression in vivo (data not shown). These
results suggest that hASC-derived periostin promotes in vivo growth
of A549 cells.
3.5. LPA-activated hASCs stimulate adhesion and proliferation of A549
cells through a periostin-mediated paracrine mechanism
Periostin has been reported to stimulate adhesion and invasion of
various cancer cells, including ovary, breast, colon, and oral cancer cells
[23,25]. In order to explore the roles of periostin in tumorigenic potentials
of A549 cells, we determined the adhesive capability of A549 cells on
periostin-coated dishes. Recombinant periostin induced dose-dependent
stimulationof adhesionofA549 cells (Supplementary Fig. 1A). In addition,
treatment of A549 cells with periostin stimulated proliferation of A549
cells in vitro (Supplementary Fig. 1B). These results suggest that periostin
can stimulate tumorigenic potentials of A549 cells by stimulating
adhesion and proliferation of tumor cells.
In order to determine whether LPA-activated hASCs promote
adhesion and proliferation of A549 cells through a periostin-dependent
mechanism, the effects of conditionedmedium from LPA-treated hASCs
(LPACM)onadhesionandproliferationofA549 cellswere examined. As
shown in Fig. 5A, higher levels of periostin proteinwere detected in LPA
CM, compared with conditioned medium from mock-treated hASCs
(control CM), and transfection of hASCs with si-periostin resulted in
completely abrogated secretion of periostin from hASCs. LPA CM
derived from si-control-transfected hASCs stimulated adhesion and
proliferation of A549 cells in vitro (Fig. 5B and C). However, LPA CM
obtained from si-periostin-transfected hASCs did not stimulate adhe-
sion and proliferation of A549 cells. These results suggest that periostin
secreted fromLPA-activatedhASCspromotes adhesion andproliferation
of A549 cells.
To further conﬁrm these results, we performed immunodepletion of
periostin from LPA CM with anti-periostin antibody and evaluated the
effects of periostin-depleted LPA CM on adhesion and proliferation of
A549 cells. As shown in Fig. 6A, periostin was speciﬁcally immunode-
pleted from LPA CM with anti-periostin antibody but not with control
antibody. Periostin-depleted LPA CM did not stimulate adhesion and
proliferation of A549 cells (Fig. 6B andC), in contrast to potent stimulation
of adhesion and proliferation of A549 cells by control antibody-treated
LPA CM. These results support the suggestion that periostin plays a key
role in LPA CM-stimulated adhesion and proliferation of A549 cells.
4. Discussion
In the present study, we demonstrated that A549 CM induced
periostin expression in hASCs through an LPA–LPA1-dependent mech-
anism. Consistently, we previously reported that conditioned medium
Fig. 3. Role of periostin in hASC-stimulated growth of A549 xenograft tumors. (A) hASCs were infected with sh-control or sh-periostin lentiviruses. A549 cells were injected alone or
both A549 cells and lentivirus-infected hASCs were subcutaneously co-injected into nude mice. Mice were then photographed at 4 weeks after injection and xenograft tumors were
photographed after sacriﬁce of mice. (B) Volume of xenograft tumors was measured at the indicated time points. Data are expressed as mean±SD (n=18). *, pb0.05; #, pb0.01 vs
A549+sh-periostin/hASCs. (C) Weights of the tumor mass were quantiﬁed and expressed as mean±SD (n=18). * indicates pb0.05. Representative data from three different
experiments are shown.
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expression of periostin in hASCs [29]. Up-regulation of periostin
expression by several extracellular agonists, including TGF-β, BMP-2,
IL-4, and IL-13, in different cell types has been reported [31–33].
However, implication of G protein-coupled receptors in regulation of
periostin expression is still elusive. LPA exerts its cellular responses
through activation of ﬁve known G protein-coupled receptors, LPA1–5
[34]. In addition to its role in LPA-stimulated periostin expression,
LPA1 mediated LPA-induced migration and differentiation of hASCs to
α-SMA-positive CAFs in vitro [21–23]. In addition, shRNA-mediated
silencing of LPA1 abrogated LPA-stimulated secretion of angiogenic
factors, vascular endothelial growth factors, and stromal cell-derived
factor-1α from hASCs in vitro [35] and blocked hASC-stimulated tumor
angiogenesis in vivo [23]. We have reported the existence of LPA in the
A549 CM and the concentration of LPA in A549 CMwas estimated to be
approximately 0.55±0.02 μM [23]. Taken together, these results
suggest a key role of LPA1 in LPA-stimulated pro-tumorigenic responses
of hASCs, including differentiation to CAFs, secretion of angiogenic
cytokines, and periostin expression.
LPA is generated by the concerted action of multiple enzymes
including phospholipase D, diacylglycerol kinase, phospholipase A,
autotaxin (also called lysophospholipase D), and monoacylglycerol
kinase [18,20,36]. Autotaxin, which was originally identiﬁed as a cell
motility-stimulating factor from CM of melanoma [37,38]. Enhanced
expression of autotaxin has been reported to be associated with
increased invasiveness and motility of cancer cells, including breast
cancer cells and glioblastoma cells [39,40]. However, we observed that
autotaxin mRNA was not detected in A549 cells, whereas hASCsexpressed high levels of autotaxin in contrast to lack of LPA in hASC
CM [23]. Therefore, it is likely that autotaxin is not responsible for the
high levels of LPA in A549 CM, although the mechanisms associated
with the high levels of LPA in A549 CM need to be clariﬁed further.
Conditioned medium from tumor cells has been shown to induce
differentiation of bonemarrow-derivedMSCs toα-SMA-positive CAFs
[17,41]. Bonemarrow-derived MSCs have been reported to contribute
to formation of CAFs or myoﬁbroblasts in a mouse pancreatic
insulinoma model [42] and in a subcutaneous pancreatic xenograft
tumor [43]. In addition, A549 CM promoted in vivo and in vitro
differentiation of hASCs to CAFs expressing α-SMA, VEGF, and SDF-1
through an LPA-mediatedmechanism [21,23]. In the present study,we
showed that LPA-stimulated periostin expression occurred in advance
of α-SMA expression in hASCs (Fig. 1) and silencing of periostin
expression using siRNA or shRNA abrogated LPA-stimulated α-SMA
expression in vitro. In addition, shRNA-mediated depletion of periostin
expression abolished differentiation of hASCs to α-SMA-positive CAFs
in vivo. Periostin was expressed in stromal cells of pancreatic ductal
adenocarcinoma and cancer cell supernatants stimulated periostin
secretion from pancreatic stellate cells [44]. Recombinant periostin
induced an increase in α-SMA, periostin, collagen-1, ﬁbronectin, and
TGF-β1 expression in pancreatic stellate cells and siRNA-mediated
silencing of endogenous periostin expression resulted in reduced
expression of ﬁbronectin, collagen-1, and α-SMA [44]. In contrast to
high expression of periostin in hASCs, periostin was not expressed in
A549 cells and recombinant periostin did not induce periostin
expression in A549 cells (Supplementary Fig. 2). Taken together,
these results support the suggestion that LPA-dependent periostin
Fig. 4. Role of periostin in differentiation of hASCs to CAFs in xenograft tumor tissues. (A) Expression of α-SMA in xenograft tissues from Fig. 3 were determined by immunostaining.
Scale bar=100 μm. (B) hASCs were labeled with the ﬂuorescent dye CM-Dil prior to co-transplantation with A549 cells into nude mice. Expression of α-SMA and periostin in
xenograft tissues was determined by immunostaining. Images of periostin (green color) and α-SMA (cyan color) expression were overlaid with images of hASCs (CM-Dil-positive
cells, red color) and nuclei (DAPI, blue color). Arrows indicate co-expression of periostin and α-SMA in CM-Dil-positive cells within tumor tissues transplanted with A549 plus sh-
control/hASCs. Arrowheads indicate no expression of periostin and α-SMA in CM-Dil-positive sh-periostin/hASCs co-transplanted with A549 cells. Scale bar=100 μm. (C) Analysis
of α-SMA expression in CM-Dil-positive hASCs in xenograft tumors. Areas of both α-SMA-positive and CM-Dil-positive cells in the images (A549 plus sh-control/hASCs; A549 plus
sh-periostin/hASCs) were quantiﬁed using Image J software and relative percentages ofα-SMA-positive cells in total CM-Dil-positive cells were calculated as described in “Materials
and methods”. * Indicates pb0.05. (n=18 per each group, 72 ﬁelds per group). (D) Quantiﬁcation of A549 cells in xenograft tumors. Areas of CM-Dil-positive hASCs and CM-Dil-
negative A549 cells in the images (A549 plus sh-control/hASCs; A549 plus sh-periostin/hASCs) were quantiﬁed using Image J software and relative ratio of A549 cells to hASCs were
calculated. * Indicates pb0.05.
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to α-SMA-positive CAFs, albeit the molecular mechanism by which
periostin stimulates differentiation of hASCs to CAFs should be further
clariﬁed.
Bone marrow-derived MSCs have been reported to stimulate
tumorigenesis and angiogenesis in xenograft transplantation animal
models [15,17]. MSCs have been known to stimulate tumor angiogen-
esis by secretion of vascular endothelial growth factors in pancreatic
carcinoma [45]. Furthermore, MSCs co-injected with human breast
carcinoma cells into a subcutaneous site by xenograft transplantation
stimulated metastatic potency of breast carcinoma by secretion ofchemokine CCL5 [16]. In addition, hASCs stimulated growth and/or
metastasis of several cancer cells, including breast, colon, and prostate
cancer [46–48]. They stimulated angiogenesis in a VEGF-dependent
paracrine fashion and augmented tumor angiogenesis in an A549
xenograft tumormodel [23,35]. In the present study,we demonstrated
that periostin plays a key role in hASC-stimulated growth of A549
xenograft tumors in vivo. Recombinant periostin protein induced an
increase in adhesion and proliferation of A549 cells in vitro. LPA CM
fromhASCs promoted adhesion andproliferation of A549 cells through
a periostin-dependent mechanism. However, LPA-induced secretion
of VEGF and SDF-1 was not affected by silencing of periostin
Fig. 5. Effects of siRNA-mediated silencing of periostin expression in LPA CM-stimulated adhesion and proliferation of A549 cells. (A) hASCs were transfected with si-control or si-
periostin, followed by treatment with 10 μM LPA or vehicles for 2 days, and protein levels of periostin in LPA CM and control CM were determined by Western blotting. (B) 96-well
plates were coated with LPA CM or control CM, and adhesion of A549 cells onto the plates was determined. (C) A549 cells were treated with 50% control CM or LPA CM for 4 days and
proliferation of A549 cells was determined. Data are expressed as mean±SD (n=4). *, pb0.01.
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not be implicated in hASC-stimulated secretion of angiogenic factors
and tumor angiogenesis. Accumulating evidence suggests that high
expression of periostin is associated with tumorigenesis, metastasis,
and angiogenesis in various carcinoma types [25]. Periostin deposition
was observed in cancer-associated stroma in various cancer types,
including lung and colon [27,49,50]. Bone metastases from breast
cancer induced over-expression of periostin by surrounding stromal
cells [51]. Periostin has been reported to support adhesion of various
carcinoma cells, including ovarian, breast, colon, and oral cancerFig. 6. Effects of periostin immunodepletion on LPA CM-stimulated adhesion and prolifera
immobilized with anti-periostin (+) or control (−) antibodies for immunodepletion of p
immunoprecipitation were determined by Western blotting. (B) 96-well plates were coa
medium, and adhesion of A549 cells onto the plates was determined. (C) A549 cells were tre
conditioned medium for 4 days and proliferation of A549 cells was determined. Data are exthrough an integrin-dependent mechanism [52–55]. Taken together,
these results suggest that hASCs stimulate tumor growth through
secretion of not only angiogenic factors but also periostin.
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